Dexketoprofen trometamol: Clinical evidence supporting its role as a painkiller

Expert Review of Neurotherapeutics

Volumn 8, Issue 11, 2008, Pages 1625-1640

  Barbanoj Rodríguez, Manuel J ^a,b,c   Antonijoan Arbós, Rosa M ^a,b,c   Amaro, Salvador Rico ^a,b,c  

^a Institut de Recerca   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Analgesia; Dexketoprofen; Injectable; NSAID; Pain; Special population; Therapeutic clinical trial

Indexed keywords

ANTICOAGULANT AGENT; BUPIVACAINE; DEXKETOPROFEN; DICLOFENAC; DIPYRONE; HEPARIN; IBUPROFEN; KETOPROFEN; KETOROLAC; LIDOCAINE; MEPIVACAINE; METOCLOPRAMIDE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; ROFECOXIB; TRAMADOL;

ABDOMINAL PAIN; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; BONE METASTASIS; CANCER PAIN; CHIRALITY; CLINICAL TRIAL; CONTACT DERMATITIS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ENANTIOMER; FEVER; GERIATRIC PATIENT; HEADACHE; HUMAN; HYPOTENSION; IDIOSYNCRATIC HYPERSENSITIVITY REACTION; KIDNEY COLIC; KIDNEY FAILURE; LIPOPHILICITY; LIVER FAILURE; LIVER INJURY; LOW BACK PAIN; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; MUSCULOSKELETAL PAIN; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PAIN; PAIN ASSESSMENT; PATIENT CONTROLLED ANALGESIA; PHOTOALLERGY; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PAIN; PROSTAGLANDIN SYNTHESIS INHIBITION; RACEMIZATION; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SINGLE DRUG DOSE; SLEEP TIME; SOMNOLENCE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN; TREATMENT INDICATION; UPPER GASTROINTESTINAL BLEEDING; VISCERAL PAIN; VISUAL ANALOG SCALE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; HUMANS; KETOPROFEN; PAIN; TROMETHAMINE;

EID: 55849085352     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.11.1625     Document Type: Review

References (88)

1. Vane JR. Introduction: mechanism of action of NSAIDs. Br. J. Rheumatol. 35(Suppl. 1), 1-3 (1996).
2. Herrero JF, Romero-Sandoval EA, Gaitan G, Mazario J. Antinociception and the new COX inhibitors: research approaches and clinical perspectives. CNS Drug Rev. 9(3), 227-252 (2003). •• Review of research approaches on antinociception.
3. Singh P, Mittal A. Current status of COX-2 inhibitors. Mini Rev. Med. Chem. 8(1), 73-90 (2008).
4. Reasbeck PG, Rice ML, Reasbeck JC. Double-blind controlled trial of indomethacin as an adjunct to narcotic analgesia after major abdominal surgery. Lancet 2(8290), 115-118 (1982).
5. Gillies GW, Kenny GN, Bullingham RE, McArdle CS. The morphine sparing effect of ketorolac tromethamine. A study of a new, parenteral non-steroidal anti-inflammatory agent after abdominal surgery. Anaesthesia 42(7), 727-731 (1987).
6. Burns JW, Aitken HA, Bullingham RE, McArdle CS, Kenny GN. Double-blind comparison of the morphine sparing effect of continuous and intermittent i.m. administration of ketorolac. Br. J. Anaesth. 67(3), 235-238 (1991).
7. Jain NK, Kulkarni SK, Singh A. Modulation of NSAID-induced antinociceptive and anti-inflammatory effects by α2-adrenoceptor agonists with gastroprotective effects. Life Sci. 70(24), 2857-2869 (2002).
8. al-Swayeh OA, Clifford RH, del Soldato P, Moore PK. A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin. Br. J. Pharmacol. 129(2), 343-350 (2000).
9. al-Swayeh OA, Futter LE, Clifford RH, Moore PK. Nitroparacetamol exhibits anti-inflammatory and anti-nociceptive activity. Br. J. Pharmacol. 130(7), 1453-1456 (2000).
10. Benoni G, Terzi M, Adami A et al. Plasma concentrations and pharmacokinetic parameters of nitrofenac using a simple and sensitive HPLC method. J. Pharm. Sci. 84(1), 93-95 (1995).
11. McCormack K, Urquhart E. Correlation between nonsteroidal anti-inflammatory drug efficacy in a clinical pain model and the dissociation of their anti-inflammatory and analgesic properties in animals models. Clin. Drug Investig. 9, 88-97 (1995). •• Explains the dissociation of the antiinflammatory efficacy from the analgesic efficacy in animal models.
12. McCormack K. The spinal actions of nonsteroidal anti-inflammatory drugs and the dissociation between their anti-inflammatory and analgesic effects. Drugs 47 (Suppl. 5), 28-45 (1994).
13. Mauleon D, Artigas R, Garcia ML, Carganico G. Preclinical and clinical development of dexketoprofen. Drugs 52(Suppl. 5), 24-45 (1996). •• Thorough information on the development of dexketoprofen trometamol (DKP.TRIS).
14. Barbanoj MJ, Antonijoan RM, Gich I. Clinical pharmacokinetics of dexketoprofen. Clin. Pharmacokinet. 40(4), 245-262 (2001). •• Information about the clinical pharmacokinetics of DKP.TRIS.
15. Caldwell J, Hutt AJ, Fournel-Gigleux S. The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences. Biochem. Pharmacol. 37(1), 105-114 (1988).
16. Evans AM. Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs. Eur. J. Clin. Pharmacol. 42(3), 237-256 (1992).
17. Legen I, Kristl A. pH and energy dependent transport of ketoprofen across rat jejunum in vitro. Eur. J. Pharm. Biopharm. 56(1), 87-94 (2003).
18. Gich I, Barbanoj MJ, Artigas R et al. New fast-onset oral formulation of dexketoprofen. Presented at: 6th INWIN'95 (Interscience World Conference on Inflammation, Antirheumatics, Analgesics and Immunomodulators). Geneva, Switzerland, 28-30 March 1995.
19. Barbanoj MJ, Gich I, Artigas R et al. Pharmacokinetics of dexketoprofen trometamol in healthy volunteers after single and repeated oral doses. J. Clin. Pharmacol. 38(12 Suppl.), 33S-40S (1998).
20. McEwen J, De Luca M, Casini A et al. The effect of food and an antacid on the bioavailability of dexketoprofen trometamol. J. Clin. Pharmacol. 38(12 Suppl.), 41S-45S (1998).
21. Caldwell J. Xenobiotic acyl-coenzymes A: critical intermediates in the biochemical pharmacology and toxicology of carboxylic acids. Biochem. Soc. Trans. 12(1), 9-11 (1984).
22. Fears R. Lipophilic xenobiotic conjugates: the pharmacological and toxicological consequences of the participation of drugs and other foreign compounds as substrates in lipid biosynthesis. Prog. Lipid Res. 24(3), 177-195 (1985).
23. Williams K, Day R, Knihinicki R, Duffield A. The stereoselective uptake of ibuprofen enantiomers into adipose tissue. Biochem. Pharmacol. 35(19), 3403-3405 (1986).
24. Sallustio BC, Meffin PJ, Knights KM. The stereospecific incorporation of fenoprofen into rat hepatocyte and adipocyte triacylglycerols. Biochem. Pharmacol. 37(10), 1919-1923 (1988).
25. Mis R, Tost D, Ortega E. Bioinversion of ketoprofen enantiomers in several species. Methods Find. Exp. Clin. Pharmacol. 16(Suppl. 1), 81 (1994).
26. Jamali F, Lovlin R, Aberg G. Bi-directional chiral inversion of ketoprofen in CD-1 mice. Chirality 9(1), 29-31 (1997).
27. Cabre F, Fernandez F, Zapatero MI et al. Intestinal ulcerogenic effect of S(+)-ketoprofen in the rat. J. Clin. Pharmacol. 38(12 Suppl.), 27S-32S (1998).
28. Cooper SA. Ketoprofen in oral surgery pain: a review. J. Clin. Pharmacol. 28(12 Suppl.), S40-S46 (1988).
29. Hayball PJ, Nation RL, Bochner F. Enantioselective pharmacodynamics of the nonsteroidal antiinflammatory drug ketoprofen: in vitro inhibition of human platelet cyclooxygenase activity. Chirality 4(8), 484-487 (1992).
30. Ferrer X, Fernández MF, Calvo L. Anti-inflammatory activity of S-(+)-ketoprofen in the carrageenan-induced paw edema of the rat. Methods Find. Exp. Clin. Pharmacol. 16(Suppl. 1), 82 (1994).
31. Fernández MF, Ferrer X, Calvo L. Analgesic activity of S-(+)-ketoprofen in the abdominal pain induced by phenylbenzoquinone in the mouse. Methods Find. Exp. Clin. Pharmacol. 16(Suppl. 1), 83 (1994).
32. Aberg G, Ciofalo VB, Pendleton RG, Ray G, Weddle D. Inversion of (R)- to (S)-ketoprofen in eight animal species. Chirality 7(5), 383-387 (1995).
33. Gich I, Bayés M, Barbanoj MJ et al. Bioinversion of R(-)-ketoprofen following oral administration in healthy volunteers. Clin. Drug. Investig. 11, 347-353 (1996).
34. Rowland M, Tozer TN. Clinical Pharmacokinetics. Concepts and Applications. Lippincott Williams & Wilkins, PA, USA (1995).
35. Valles J, Artigas R, Crea A et al. Clinical pharmacokinetics of parenteral dexketoprofen trometamol in healthy subjects. Methods Find. Exp. Clin. Pharmacol. 28(Suppl. A), 7-12 (2006). • Clinical pharmacokinetics of parenteral DKP.TRIS.
36. Valles J, Artigas R, Bertolotti M et al. Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. Methods Find. Exp. Clin. Pharmacol. 28(Suppl. A), 29-36 (2006). • Clinical pharmacokinetics of DKP.TRIS in liver disease.
37. Valles J, Artigas R, Bertolotti M et al. Single and repeated dose pharmacokinetics of dexketoprofen trometamol in young and elderly subjects. Methods Find. Exp. Clin. Pharmacol. 28(Suppl. A), 13-19 (2006). • Clinical pharmacokinetics of DKP.TRIS in the elderly.
38. Valles J, Artigas R, Mas M et al. Pharmacokinetics of dexketoprofen trometamol in subjects with mild and moderate chronic renal insufficiency. Methods Find. Exp. Clin. Pharmacol. 28(Suppl. A), 21-28 (2006). • Clinical pharmacokinetics of DKP.TRIS in renal disease.
39. Biscarini L. Non-steroidal anti-inflammatory drugs. In: Meyler's Side Effects of Drugs. Dukes MNG, Aronson JK (Eds) Elsevier, Amsterdam, The Netherlands, 246-309 (2000).
40. Jackson ID, Heidemann BH, Wilson J, Power I, Brown RD. Double-blind, randomized, placebo-controlled trial comparing rofecoxib with dexketoprofen trometamol in surgical dentistry. Br. J. Anaesth. 92(5), 675-680 (2004).
41. Muñoz G, Berini L, Sánchez S et al. Preoperative dexketoprofen for the prevention of postoperative dental pain: a randomized double-blind clinical trial. Methods Find. Exp. Clin. Pharmacol. 20(Suppl. A), 69 (1998).
42. Ong CK, Lirk P, Seymour RA, Jenkins BJ. The efficacy of preemptive analgesia for acute postoperative pain management: a meta-analysis. Anesth. Analg. 100(3), 757-773 (2005).
43. Jimenez-Martinez E, Gasco-Garcia C, Arrieta-Blanco JJ, Gomez del Torno J, Bartolome Villar B. Study of the analgesic efficacy of dexketoprofen trometamol 25mg. vs. ibuprofen 600mg. after their administration in patients subjected to oral surgery. Med. Oral 9(2), 138-148 (2004).
44. Kehlet H, Dahl JB. The value of "multimodal" or "balanced analgesia" in postoperative pain treatment. Anesth. Analg. 77(5), 1048-1056 (1993).
45. Murphy DF. NSAIDs and postoperative pain. BMJ 306(6891), 1493-1494 (1993).
46. Joshi GP. Postoperative pain management. Int. Anesthesiol. Clin. 32(3), 113-126 (1994).
47. Vogt WE, Kübler U, Labes D, Schreiber M. Die Behandlung von Schmerzen nach ambulant durchgeführten Operationen - Dexketoprofen Trometamol vs. Tramadol. Der niedergelassene chirurg. 11, 1-5 (1999).
48. Zapata A, Cegarra F, Artigas R et al. Dexketoprofen vs tramadol: randomized double-blind trial in patients with postoperative pain. Br. J. Clin. Pharmacol. 223(Abstract 870) (2000).
49. Berti M, Albertin A, Casati A et al. A prospective, randomized comparison of dexketoprofen, ketoprofen or paracetamol for postoperative analgesia after outpatient knee arthroscopy. Minerva Anestesiol. 66(7-8), 549-554 (2000).
50. Iohom G, Walsh M, Higgins G, Shorten G. Effect of perioperative administration of dexketoprofen on opioid requirements and inflammatory response following elective hip arthroplasty. Br. J. Anaesth. 88(4), 520-526 (2002). • Efficacy of DKP.TRIS on lowering the opioid requirements and postoperative nausea and vomiting.
51. Mercorio F, De Simone R, Landi P et al. Oral dexketoprofen for pain treatment during diagnostic hysteroscopy in postmenopausal women. Maturitas 43(4), 277-281 (2002).
52. Swedberg JA, Steinbauer JR. Osteoarthritis. Am. Fam. Physician 45(2), 557-568 (1992).
53. Marenco JL, Pérez M, Navarro FJ et al. A multicentre, randomised, double-blind study to compare the efficacy and tolerability of dexketoprofen trometamol versus diclofenac in the symptomatic treatment of knee osteoarthritis. Clin. Drug Investig. 19(4), 247-256 (2000). • Clinical trial assessing the efficacy of DKP.TRIS on knee osteoarthritis.
54. Rovetta G, Monteforte P, Brignone A, Molfetta L, Buffrini L. Early-morning administration of dexketoprofen-trometamol in morning stiffness induced by nodal osteoarthritis of the hands. Int. J. Tissue React. 23(2), 63-66 (2001).
55. Metscher B, Kubler U, Jahnel-Kracht H. [Dexketoprofen-trometamol and tramadol in acute lumbago]. Fortschr Med. Orig. 118(4), 147-151 (2001).
56. Leman P, Kapadia Y, Herington J. Randomised controlled trial of the onset of analgesic efficacy of dexketoprofen and diclofenac in lower limb injury. Emerg. Med. J. 20(6), 511-513 (2003).
57. Hartmann LC, Zahasky KM, Grendahl DC. Management of cancer pain. Safe, adequate analgesia to improve quality of life. Postgrad. Med. 107(3), 267-272, 275-276 (2000).
58. Cheville AL. Pain management in cancer rehabilitation. Arch. Phys. Med. Rehabil. 82(3 Suppl. 1), S84-S87 (2001).
59. Rodriguez MJ, Contreras D, Galvez R et al. Double-blind evaluation of short-term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain 104(1-2), 103-110 (2003).
60. Allais G, De Lorenzo C, Airola G, Peano S, Benedetto C. Dexketoprofen trometamol in the treatment of acute migraine attack. Minerva Med. 91(7-8), 153-159 (2000).
61. Borras L, Gómez M, Sala J et al. Physicochemical compatibility of dexketoprofen trometamol injectable solution with pharmaceutical products of frequent combined use in the clinical setting. Proceedings of the 20th Congress of the Spanish Clinical Pharmacology Society. Puerto de la Cruz, Tenerife, Spain, 29 October-2 November 2006. Basic Clin. Pharmacol. Toxicol. (Suppl. 1), 56(poster FT4) (2006).
62. Barbanoj MJ. Clinical pharmacokinetics of dexketoprofen trometamol: recent studies. Methods Find. Exp. Clin. Pharmacol. 28(Suppl. A), 3-5 (2006).
63. Zapata A, Sala J, Valles J, Ballarín M. Bioavailavility of dexketoprofen trometamol granules for oral solution: a new formulation for the treatment of acute pain. In: 5th EFIC Congress. Istanbul, Turkey, 13-16 September 2006.
64. Ballarín M, Sala J, Artigas R. Revisión de la eficacia de dexketoprofeno trometamol inyectable. Dolor 18, 133-148 (2003).
65. Sanchez-Carpena J, Dominguez-Hervella F, Garcia I et al. Comparison of intravenous dexketoprofen and dipyrone in acute renal colic. Eur. J. Clin. Pharmacol. 63(8), 751-760 (2007). • Clinical trial of DKP.TRIS versus dipyrone in acute renal colic.
66. Debré F, Zapata A, Bertolotti M, Capriati A, Ballarín M. The analgesic efficay of dexketoprofen trometamol I.V. in renal colic: a double blind, randomised, active, controlled trial versus ketoprofen. Presented at: 10th World Congress on Pain, IASP. San Diego, CA, USA, 17-22 August 2002, 1590-P1138.
67. Sánchez Carpena J, Domínguez-Hervella F, García I et al. Intravenous dexketoprofen versus dypirone followed by an oral treatment in acute renal colic. Presented at: The Pain Society (The British Chapter of IASP). Annual Scientific Meeting. Glasgow, Scotland, 1-4 April 2003, P24.
68. Rawal N. Organization of acute pain services - a low-cost model. Acta Anaesthesiol. Scand. Suppl. 111, 188-190 (1997).
69. Peat S, Paredes I, Bertolotti M, Capriati A. Dexketoprofen trometamol versus tramadol in the relief of pain following major orthopaedic surgery. Presented at: 10th World Congress on Pain, IASP. San Diego, CA, USA, 17-22 August 2002, 945-P215.
70. Hanna MH, Elliott KM, Stuart-Taylor ME et al. Comparative study of analgesic efficacy and morphine-sparing effect of intramuscular dexketoprofen trometamol with ketoprofen or placebo after major orthopaedic surgery. Br. J. Clin. Pharmacol. 55(2), 126-133 (2003). • Clinical trial that provides information on the efficacy and morphine-sparing effect of DKP.TRIS.
71. Zippel H, Wagenitz A. Comparison of the efficacy and safety of intravenously administered dexketoprofen trometamol and ketoprofen in the management of pain after orthopaedic surgery: a multicentre, double-blind, randomised, parallel-group clinical trial. Clin. Drug Investig. 26(9), 517-528 (2006). • Clinical trial for the indication of management of pain after orthopedic surgery.
72. Miralles F, Zapata A, Mas M et al. Morphine sparing effect of dexketoprofen trometamol when used in the treatment of postoperative pain after major abdominal surgery. Presented at: 10th World Congress on Pain, IASP. San Diego, CA, USA, 17-22 August 2002, 952-P222.
73. Zippel H, Wagenitz A. A multicentre, randomised, double-blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain. Clin. Drug Investig. 27(8), 533-543 (2007). • Clinical trial of DKP.TRIS versus diclofenac for the treatment of acute low back pain.
74. Valles J, Borras L, Sala J, Artigas R. Perfil de seguridad del dexketoprofeno trometamol en asistencia primaria. Presented at: IV Jornadas Nacionales de Farmacovigilancia. Valencia, Spain, 4 April 2003.
75. Zabala S, Calpe MJ, Perez G, Lerin FJ, Mouronval L. Neutropenia, thrombocytopenia and hepatic injury associated with dexketoprofen trometamol therapy in a previously healthy 35-year-old woman. J. Clin. Pharm. Ther. 33(1), 79-81 (2008).
76. Goday-Bujan JJ, Rodriguez-Lozano J, Martinez-Gonzalez MC, Fonseca E. Photoallergic contact dermatitis from dexketoprofen: study of 6 cases. Contact Dermatitis 55(1), 59-61 (2006).
77. Asensio T, Sanchis ME, Sanchez P, Vega JM, Garcia JC. Photocontact dermatitis because of oral dexketoprofen. Contact Dermatitis 58(1), 59-60 (2008).
78. Laporte JR, Ibanez L, Vidal X, Vendrell L, Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf. 27(6), 411-420 (2004). •• Case-control study about the risk of upper gastrointestinal bleeding with NSAID's.
79. Catella-Lawson F, Crofford LJ. Cyclooxygenase inhibition and thrombogenicity. Am. J. Med. 110 (Suppl. 3A), 28S-32S (2001).
80. FitzGerald GA. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am. J. Cardiol. 89(6A), 26D-32D (2002).
81. Mukherjee D. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem. Pharmacol. 63(5), 817-821 (2002).
82. Flordal PA, Berggvist D, Burmark US, Ljungstrom KG, Torngren S. Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations. The Fragmin Multicentre Study Group. Eur. J. Surg. 162(10), 783-789 (1996).
83. Cohen AT, Wagner MB, Mohamed MS. Risk factors for bleeding in major abdominal surgery using heparin thromboprophylaxis. Am. J. Surg. 174(1), 1-5 (1997).
84. Miralles F, Santillán R, De la Torre R et al. Dexketoprofen versus diclofenac and placebo: a randomized double-blind trial in patients with postoperative pain. Methods Find. Exp. Clin. Pharmacol. 23(6), 58 (2001).
85. Herrero JF, Romero-Sandoval EA, Gaitán G, Mazarío J, Camposeco AL. Efectos analgésicos de los nuevos inhibidores de las ciclooxigenasas: evidencias experimentales y expectativas clínicas. Rev. Soc. Esp. Dolor 10, 518-532 (2003).
86. Martin MJ, Jimenez MD, Motilva V. New issues about nitric oxide and its effects on the gastrointestinal tract. Curr. Pharm. Des. 7(10), 881-908 (2001).
87. Gaitan G, Ahuir FJ, Del Soldato P, Herrero JF. Comparison of the antinociceptive activity of two new NO-releasing derivatives of the NSAID S-ketoprofen in rats. Br. J. Pharmacol. 143(5), 533-540 (2004). •• Application of additional strategies to improve DKP.TRIS painkiller activity.
88. Carganico G, Mauleón D, García ML. A novel arylpropionic derivative, its method of preparation and its application as an analgesic. International Patent PCT. WO-94/11332; (Prior. ES9202260), Spain, 10 November (1992).